Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis

Carla G. Monico, Sandro Rossetti, Heidi A. Schwanz, Julie B. Olson, Patrick A. Lundquist, D. Brian Dawson, Peter C Harris, Dawn S. Milliner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Mutations in AGXT, a locus mapped to 2q37.3, cause deficiency of liver-specific alanine:glyoxylate aminotransferase (AGT), the metabolic error in type 1 primary hyperoxaluria (PH1). Genetic analysis of 55 unrelated probands with PH1 from the Mayo Clinic Hyperoxaluria Center, to date the largest with availability of complete sequencing across the entire AGXT coding region and documented hepatic AGT deficiency, suggests that a molecular diagnosis (identification of two disease alleles) is feasible in 96% of patients. Unique to this PH1 population was the higher frequency of G170R, the most common AGXT mutation, accounting for 37% of alleles, and detection of a new 3′ end deletion (Ex 11_3′UTR del). A described frameshift mutation (c.33_34insC) occurred with the next highest frequency (11%), followed by F152I and G156R (frequencies of 6.3 and 4.5%, respectively), both surpassing the frequency (2.7%) of I244T, the previously reported third most common pathogenic change. These sequencing data indicate that AGXT is even more variable than formerly believed, with 28 new variants (21 mutations and seven polymorphisms) detected, with highest frequencies on exons 1, 4, and 7. When limited to these three exons, molecular analysis sensitivity was 77%, compared with 98% for whole-gene sequencing. These are the first data in support of comprehensive AGXT analysis for the diagnosis of PH1, obviating a liver biopsy in most well-characterized patients. Also reported here is previously unavailable evidence for the pathogenic basis of all AGXT missense variants, including evolutionary conservation data in a multisequence alignment and use of a normal control population.

Original languageEnglish (US)
Pages (from-to)1905-1914
Number of pages10
JournalJournal of the American Society of Nephrology
Volume18
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Mutation
Exons
Liver
Alleles
Hyperoxaluria
Genes
Frameshift Mutation
Population
Biopsy
Primary hyperoxaluria type 1
Alanine-glyoxylate transaminase

ASJC Scopus subject areas

  • Nephrology

Cite this

Monico, C. G., Rossetti, S., Schwanz, H. A., Olson, J. B., Lundquist, P. A., Dawson, D. B., ... Milliner, D. S. (2007). Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. Journal of the American Society of Nephrology, 18(6), 1905-1914. https://doi.org/10.1681/ASN.2006111230

Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. / Monico, Carla G.; Rossetti, Sandro; Schwanz, Heidi A.; Olson, Julie B.; Lundquist, Patrick A.; Dawson, D. Brian; Harris, Peter C; Milliner, Dawn S.

In: Journal of the American Society of Nephrology, Vol. 18, No. 6, 06.2007, p. 1905-1914.

Research output: Contribution to journalArticle

Monico, Carla G. ; Rossetti, Sandro ; Schwanz, Heidi A. ; Olson, Julie B. ; Lundquist, Patrick A. ; Dawson, D. Brian ; Harris, Peter C ; Milliner, Dawn S. / Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. In: Journal of the American Society of Nephrology. 2007 ; Vol. 18, No. 6. pp. 1905-1914.
@article{4ffb587e2ab54c0989a4ae7d777afd2a,
title = "Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis",
abstract = "Mutations in AGXT, a locus mapped to 2q37.3, cause deficiency of liver-specific alanine:glyoxylate aminotransferase (AGT), the metabolic error in type 1 primary hyperoxaluria (PH1). Genetic analysis of 55 unrelated probands with PH1 from the Mayo Clinic Hyperoxaluria Center, to date the largest with availability of complete sequencing across the entire AGXT coding region and documented hepatic AGT deficiency, suggests that a molecular diagnosis (identification of two disease alleles) is feasible in 96{\%} of patients. Unique to this PH1 population was the higher frequency of G170R, the most common AGXT mutation, accounting for 37{\%} of alleles, and detection of a new 3′ end deletion (Ex 11_3′UTR del). A described frameshift mutation (c.33_34insC) occurred with the next highest frequency (11{\%}), followed by F152I and G156R (frequencies of 6.3 and 4.5{\%}, respectively), both surpassing the frequency (2.7{\%}) of I244T, the previously reported third most common pathogenic change. These sequencing data indicate that AGXT is even more variable than formerly believed, with 28 new variants (21 mutations and seven polymorphisms) detected, with highest frequencies on exons 1, 4, and 7. When limited to these three exons, molecular analysis sensitivity was 77{\%}, compared with 98{\%} for whole-gene sequencing. These are the first data in support of comprehensive AGXT analysis for the diagnosis of PH1, obviating a liver biopsy in most well-characterized patients. Also reported here is previously unavailable evidence for the pathogenic basis of all AGXT missense variants, including evolutionary conservation data in a multisequence alignment and use of a normal control population.",
author = "Monico, {Carla G.} and Sandro Rossetti and Schwanz, {Heidi A.} and Olson, {Julie B.} and Lundquist, {Patrick A.} and Dawson, {D. Brian} and Harris, {Peter C} and Milliner, {Dawn S.}",
year = "2007",
month = "6",
doi = "10.1681/ASN.2006111230",
language = "English (US)",
volume = "18",
pages = "1905--1914",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "6",

}

TY - JOUR

T1 - Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis

AU - Monico, Carla G.

AU - Rossetti, Sandro

AU - Schwanz, Heidi A.

AU - Olson, Julie B.

AU - Lundquist, Patrick A.

AU - Dawson, D. Brian

AU - Harris, Peter C

AU - Milliner, Dawn S.

PY - 2007/6

Y1 - 2007/6

N2 - Mutations in AGXT, a locus mapped to 2q37.3, cause deficiency of liver-specific alanine:glyoxylate aminotransferase (AGT), the metabolic error in type 1 primary hyperoxaluria (PH1). Genetic analysis of 55 unrelated probands with PH1 from the Mayo Clinic Hyperoxaluria Center, to date the largest with availability of complete sequencing across the entire AGXT coding region and documented hepatic AGT deficiency, suggests that a molecular diagnosis (identification of two disease alleles) is feasible in 96% of patients. Unique to this PH1 population was the higher frequency of G170R, the most common AGXT mutation, accounting for 37% of alleles, and detection of a new 3′ end deletion (Ex 11_3′UTR del). A described frameshift mutation (c.33_34insC) occurred with the next highest frequency (11%), followed by F152I and G156R (frequencies of 6.3 and 4.5%, respectively), both surpassing the frequency (2.7%) of I244T, the previously reported third most common pathogenic change. These sequencing data indicate that AGXT is even more variable than formerly believed, with 28 new variants (21 mutations and seven polymorphisms) detected, with highest frequencies on exons 1, 4, and 7. When limited to these three exons, molecular analysis sensitivity was 77%, compared with 98% for whole-gene sequencing. These are the first data in support of comprehensive AGXT analysis for the diagnosis of PH1, obviating a liver biopsy in most well-characterized patients. Also reported here is previously unavailable evidence for the pathogenic basis of all AGXT missense variants, including evolutionary conservation data in a multisequence alignment and use of a normal control population.

AB - Mutations in AGXT, a locus mapped to 2q37.3, cause deficiency of liver-specific alanine:glyoxylate aminotransferase (AGT), the metabolic error in type 1 primary hyperoxaluria (PH1). Genetic analysis of 55 unrelated probands with PH1 from the Mayo Clinic Hyperoxaluria Center, to date the largest with availability of complete sequencing across the entire AGXT coding region and documented hepatic AGT deficiency, suggests that a molecular diagnosis (identification of two disease alleles) is feasible in 96% of patients. Unique to this PH1 population was the higher frequency of G170R, the most common AGXT mutation, accounting for 37% of alleles, and detection of a new 3′ end deletion (Ex 11_3′UTR del). A described frameshift mutation (c.33_34insC) occurred with the next highest frequency (11%), followed by F152I and G156R (frequencies of 6.3 and 4.5%, respectively), both surpassing the frequency (2.7%) of I244T, the previously reported third most common pathogenic change. These sequencing data indicate that AGXT is even more variable than formerly believed, with 28 new variants (21 mutations and seven polymorphisms) detected, with highest frequencies on exons 1, 4, and 7. When limited to these three exons, molecular analysis sensitivity was 77%, compared with 98% for whole-gene sequencing. These are the first data in support of comprehensive AGXT analysis for the diagnosis of PH1, obviating a liver biopsy in most well-characterized patients. Also reported here is previously unavailable evidence for the pathogenic basis of all AGXT missense variants, including evolutionary conservation data in a multisequence alignment and use of a normal control population.

UR - http://www.scopus.com/inward/record.url?scp=34249874881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249874881&partnerID=8YFLogxK

U2 - 10.1681/ASN.2006111230

DO - 10.1681/ASN.2006111230

M3 - Article

C2 - 17460142

AN - SCOPUS:34249874881

VL - 18

SP - 1905

EP - 1914

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 6

ER -